ORBIMED ADVISORS LLC recently filed their 13F report for the third quarter of 2022, which ended on 2022-09-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
Orbimed Advisors is an investment company that was founded in 1989 with a vision to “invest across the spectrum of healthcare companies from venture capital start-ups to large multinational companies.” The company started with its first public equity fund in 1989 and would expand to offer long/short equity and private equity investments by 1993. The company would continue to grow and expand, opening its Mumbai and Shanghai offices in Asia in 2007 and beginning its international expansion. In 2010, Orbimed Advisors would expand to the Middle East, opening an office in Israel. The company would then launch its first health care royalties and credit opportunities fund in 2011 and another royalty opportunities fund in 2015. Orbimed Advisors currently has approximately $15 billion in total assets under management spread across 5 accounts, all of which are discretionary. While its number of accounts has remained relatively steady in recent years, its total assets under management has increased significantly, growing from $1.2 billion back in 2010 to over 10 times that amount today.
As of the latest 13F report, the guru’s equity portfolio contained 130 stocks valued at a total of $5.36Bil. The top holdings were SVA(6.35%), BMY(3.43%), and HUM(3.15%).
According to GuruFocus data, these were ORBIMED ADVISORS LLC’s top five trades of the quarter.
Compass Therapeutics Inc
ORBIMED ADVISORS LLC reduced their investment in NAS:CMPX by 3,169,428 shares. The trade had a 0.25% impact on the equity portfolio. During the quarter, the stock traded for an average price of $4.25.
On 11/15/2022, Compass Therapeutics Inc traded for a price of $4.69 per share and a market cap of $592.47Mil. The stock has returned 30.42% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Compass Therapeutics Inc has a price-book ratio of 4.08 and a EV-to-Ebitda ratio of -11.86.
Theseus Pharmaceuticals Inc
During the quarter, ORBIMED ADVISORS LLC bought 192,000 shares of NAS:THRX for a total holding of 17,233,668. The trade had a 0.02% impact on the equity portfolio. During the quarter, the stock traded for an average price of $5.82.
On 11/15/2022, Theseus Pharmaceuticals Inc traded for a price of $6.64 per share and a market cap of $257.06Mil. The stock has returned -60.94% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Theseus Pharmaceuticals Inc has a price-book ratio of 1.18 and a EV-to-Ebitda ratio of -1.11.
Keros Therapeutics Inc
ORBIMED ADVISORS LLC reduced their investment in NAS:KROS by 410,683 shares. The trade had a 0.39% impact on the equity portfolio. During the quarter, the stock traded for an average price of $50.46.
On 11/15/2022, Keros Therapeutics Inc traded for a price of $44.63 per share and a market cap of $1.23Bil. The stock has returned -27.67% over the past year.
GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Keros Therapeutics Inc has a price-book ratio of 4.82, a EV-to-Ebitda ratio of -12.36 and a price-sales ratio of 52.19.
Horizon Therapeutics PLC
The guru sold out of their 2,108,555-share investment in NAS:HZNP. Previously, the stock had a 3.07% weight in the equity portfolio. Shares traded for an average price of $69.87 during the quarter.
On 11/15/2022, Horizon Therapeutics PLC traded for a price of $75.915 per share and a market cap of $17.06Bil. The stock has returned -31.27% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Horizon Therapeutics PLC has a price-earnings ratio of 30.85, a price-book ratio of 3.44, a EV-to-Ebitda ratio of 16.41 and a price-sales ratio of 4.74.
The price-to-GF Value ratio is 0.60, earning the stock a GF Value rank of 8.
Turning Point Therapeutics Inc
The guru sold out of their 2,012,250-share investment in NAS:TPTX. Previously, the stock had a 2.76% weight in the equity portfolio. Shares traded for an average price of $75.07 during the quarter.
On 11/15/2022, Turning Point Therapeutics Inc traded for a price of $76.01 per share and a market cap of $3.81Bil. The stock has returned 13.89% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Turning Point Therapeutics Inc has a price-book ratio of 4.78, a EV-to-Ebitda ratio of -8.81 and a price-sales ratio of 3800.50.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
